Carlo Alberto Quaranta

Dr. Carlo Alberto Quaranta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Journal of Sleep Research
Verified
Journal Article
Open access
LPLudovica Pasca
Ludovica Pasca
Carlo Alberto QuarantaCarlo Alberto Quaranta
Carlo Alberto Quaranta
SGSerena Grumi
Serena Grumi
MZMartina Paola Zanaboni
Martina Paola Zanaboni
ATAnna Tagliabue
Anna Tagliabue
VGValentina De Giorgis
Valentina De Giorgis
Summary: Sleep problems are common in neurological conditions for which ketogenic dietary therapies (KDTs) are recognised as an effective intervention (drug‐resistant epilepsy, autism spectrum disorder, and migraine). Given the composite framework of action of ketogenic dietary therapies, the prevalence of sleep disturbance, and the importance of sleep regulation, the present scoping review aimed at identifying and mapping available evidence of the effects of ketogenic dietary therapies on sleep. A comprehensive web‐based literature search was performed retrieving publications published to June 2023 using PubMed and Scopus, yielding to 277 records. Twenty papers were finally selected and included in the review. Data were abstracted by independent coders. High variability was identified in study design and sleep outcome evaluation among the selected studies. Several changes in sleep quality and sleep structure under ketogenic dietary therapies were found, namely an improvement of overall sleep quality, improvement in the difficulty falling asleep and nighttime awakenings, improvement in daytime sleepiness and an increase of REM sleep. The relevance and possible physiological explanations of these changes, clinical recommendations, and future directions in the field are discussed.

29 May 2024 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
MCMiriam Corradini
Miriam Corradini
MZMartina Paola Zanaboni
Martina Paola Zanaboni
CVCostanza Varesio
Costanza Varesio
MCMassimiliano Celario
Massimiliano Celario
ECElena Capelli
Elena Capelli
VGValentina De Giorgis
Valentina De Giorgis

6 January 2025 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
SPStefano Parravicini
Stefano Parravicini
Carlo Alberto QuarantaCarlo Alberto Quaranta
Carlo Alberto Quaranta
MDM. I. Dainesi
M. I. Dainesi
ABA. Berardinelli
A. Berardinelli
Aim: To study unexplored neuropsychological domains in the characterization of the Central Nervous System (CNS) involvement in Duchenne Muscular Dystrophy (DMD) that could be relevant based on the recent findings about dystrophin expression in human CNS.Method: A sample of DMD individuals (n = 20) underwent a neuropsychological battery encompassing standard cognitive assessments but also less explored social cognition skills. Wechsler scales and a developmental neuropsychological assessment (NEPSY-II) were adopted.Results: Our sample performed significantly worse than the reference scores in the “social cognition” sub-items of the NEPSY-II; the difference persisted even when splitting the sample by Dp140 depletion or cognitive deficit. The difference in the “affect recognition” scores between the Dp140 + and the Dp140− subgroups was confirmed even after excluding the subjects with a cognitive deficit.Interpretation: Dystrophin is highly expressed in structures involved in the brain networks underlying some social cognition skills. Our results, which provide additional preliminary evidence of a possible specific impairment in this area, underscore the importance of considering social cognition as another feature of the CNS phenotype of DMD, consistent with a few other previous reports.

15 January 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
LPLudovica Pasca
Ludovica Pasca
FMFederica Morelli
Federica Morelli
GCGuido Catalano
Guido Catalano
Carlo Alberto QuarantaCarlo Alberto Quaranta
Carlo Alberto Quaranta
HVHelene Vitali
Helene Vitali
VFValentina Franco
Valentina Franco
Introduction Children with septo-optic-pituitary dysplasia (SOD) may experience a range of visual impairments and hormonal dysfunctions beyond developmental delay/intellectual disability. The literature describes sleep fragmentation, circadian rhythm disruptions and reduced sleep efficiency. These manifestations are believed to be closely linked to both structural and functional abnormalities associated with SOD, potentially disrupting the natural circadian rhythm. Both anomalies in midline brain structures and decreased visual input could potentially impact melatonin secretion, although a distinct melatonin profile for SOD patients has yet to be identified. Furthermore, the specific contribution of these factors to sleep disturbances in SOD remains unexplored. The aim of this study is to evaluate the quality of sleep and its characteristics, along with the melatonin profile, among paediatric patients diagnosed with SOD. A comparison will be made between these findings and those of children with isolated bilateral visual impairment, as well as patients with agenesis of the corpus callosum. Methods and analysis Participants aged between 3 and 18 years previously diagnosed with SOD will be recruited prospectively. Each participant will be assessed at baseline and at each follow-up visit scheduled to evaluate the clinical course. Sleep quality and daytime sleepiness changes will be tracked using actigraphic assessment, standardised sleep questionnaires and a sleep EEG. Additionally, plasma and salivary melatonin profiles will be assessed for each participant. Ethics and dissemination This study has been approved by local Ethics Committee (N°0049187/23). The study findings will be shared through publication in an international peer-reviewed journal and presented at both national and international conferences. Trial registration number NCT06262152.

18 August 2025 in Genes
Verified
Journal Article
Open access
PDF file
Carlo Alberto QuarantaCarlo Alberto Quaranta
Carlo Alberto Quaranta
AGAlice Gardani
Alice Gardani
GAGiulia Andorno
Giulia Andorno
APAnna Pichiecchio
Anna Pichiecchio
SGSimone Gana
Simone Gana
SOSimona Orcesi
Simona Orcesi
Background/Objectives: Hereditary spastic paraplegias (HSPs) comprise a heterogenous spectrum of rare neurogenetic disorders predominantly characterized by progressive spasticity and weakness of the lower extremities. Among autosomal-dominant forms of HSP, molecular defects in the SPAST gene—particularly those associated with the SPG4 subtype—represent the most frequent genetic cause. SPAST encodes spastin, a microtubule-severing ATPase, crucial for cytoskeletal remodeling, neuronal connectivity, and intracellular trafficking. Disruption of spastin function can impair neurite outgrowth and synaptic formation, processes increasingly implicated in neurodevelopmental disorders (NDDs). Methods: We conducted a comprehensive clinical, neurological, and dysmorphological evaluation of a 4-year-old male. Standardized neuropsychological assessments were administered. Whole-exome sequencing (WES) was performed to identify underlying genetic causes. EEG and 3T-brain MRI were also acquired. Results: The proband harbored two novel de novo heterozygous missense variants in cis of the SPAST gene, displaying the typical features of early-onset and complex HSP, in addition to global developmental delay and severe autism spectrum disorder (ASD), an underexplored manifestation in this rare genetic disorder. Conclusions: These findings broaden the clinical and mutational spectrum of SPG4, underscoring the importance of considering SPAST gene analysis in patients with ASD in the early years of life and early motor delay, even in the presence of only subtle pyramidal signs. We advocate for comprehensive neuropsychiatric assessment in the diagnostic pathway of early-onset complex HSP presentations and support further investigation into the role of spastin in neuronal connectivity.

29 July 2025 in Gait & Posture
Verified
Journal Article
Open access
MCMichele Corrado
Michele Corrado
VVValeria Vacchini
Valeria Vacchini
MCMassimiliano Celario
Massimiliano Celario
CVCostanza Varesio
Costanza Varesio
CBCarla Brancaccio
Carla Brancaccio
RIRoberto De Icco
Roberto De Icco
Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a rare neurometabolic disorder caused by mutations in the SLC2A1 gene. GLUT1-DS is characterized by epilepsy, cognitive impairment, movement disorders, and gait abnormalities. In the present study we aimed to characterize gait features of GLUT1-DS by means of gait analysis based on a single inertial measurement unit. We conducted a case-control study with 32 GLUT1-DS patients (22.4 ± 13.2 years; 13 males) and 32 matched healthy participants (HS). Participants underwent inertial gait analysis, providing spatio-temporal and trunk acceleration-derived gait indexes, including harmonic ratio (HR), largest Lyapunov exponent (sLLE), log-dimensionless jerk score of accelerations (LDLJa), and step length variability (CV). Compared to HS, GLUT1-DS patients showed decreased HR (P < 0.005) across all directions, reflecting reduced symmetry and smoothness of trunk acceleration during gait. sLLE was higher in GLUT1-DS, indicating gait instability (P < 0.005), and LDLJa was elevated (P = 0.001), corroborating lower smoothness of trunk accelerations. Step length variability was also higher in GLUT1-DS patients (P = 0.001). The gait pattern of GLUT1-DS patients is marked by reduced fluidity, stability, and smoothness. Inertial gait analysis could be a valuable tool for monitoring GLUT1-DS progression and tailoring rehabilitative strategies.